Quantcast
Last updated on April 18, 2014 at 9:47 EDT

Latest Bristol-Myers Squibb Stories

2013-05-07 16:28:43

Study Meets Primary Endpoint of Non-Inferiority in Monotherapy Setting THOUSAND OAKS, Calif., May 7, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 head-to-head ASPECCT ('763) trial evaluating Vectibix(®) (panitumumab) versus Erbitux(®) (cetuximab) as a single agent for the treatment of chemorefractory metastatic colorectal cancer (mCRC) in patients with wild-type KRAS tumors (n=1,010) met its primary endpoint of non-inferiority for overall survival. The...

2013-05-06 23:03:40

Studies conducted on the blood-thinning drug Plavix indicate no benefit when taken with aspirin and may increase changes of suffering a stroke. The Law Firm of d'Oliveira & Associates wishes to inform the general public that with Plavix going generic, cases of side effects associated with the drug may increase. (PRWEB) May 06, 2013 Marketed by Bristol-Myers Squibb and Sanofi Pharmaceuticals and currently the second most commonly prescribed drug on the U.S. market, Plavix is used to...

2013-05-03 08:25:40

SAN DIEGO, May 3, 2013 /PRNewswire/ -- Ambrx today entered into a collaboration agreement with Bristol-Myers Squibb (NYSE: BMY) for the discovery and development of novel antibody drug conjugates using Ambrx's protein medicinal chemistry technology. Under terms of the agreement, Ambrx will receive an upfront payment of $15 million, funding for discovery and research activities, and potential development, regulatory and sales based milestone payments of up to $97 million per product resulting...

2013-05-02 16:28:34

SAN DIEGO, May 2, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the first quarter ended March 31, 2013. During the first quarter of 2013, Cadence reported net product revenue from sales of OFIRMEV(®) (acetaminophen) injection of $23.6 million, which includes the...

2013-05-01 14:56:37

Researchers from CHOP, Penn find better outcomes for efavirenz over nevirapine in children over age 3 in low-resource settings Researchers from The Children's Hospital of Philadelphia and the Perelman School of Medicine at The University of Pennsylvania, along with colleagues at the Botswana-Baylor Children's Clinical Centre of Excellence, conducted the first large-scale comparison of first-line treatments for HIV-positive children, finding that initial treatment with efavirenz was more...

HIV Antiretroviral Drug Has Psychoactive Effects
2013-04-22 05:22:19

redOrbit Staff & Wire Reports - Your Universe Online The psychoactivity of an antiretroviral (ARV) drug commonly used to treat HIV has been linked to its recreational use, according to research presented during the Experimental Biology 2013 conference in Boston, Massachusetts on Sunday. The medication efavirenz (which is also known under the brand names Sustiva and Stocrin) has become popular as a treatment for the virus that causes AIDS due to its ability to suppress replication of...

2013-04-16 04:21:39

HOERSHOLM, Denmark, and SAN DIEGO, April 16, 2013 /PRNewswire/ -- Santaris Pharma A/S, a privately held biopharmaceutical company focused on developing medicines targeted to disease-related mRNAs and microRNAs, today announced a worldwide strategic alliance with Bristol-Myers Squibb (NYSE: BMY) to discover and develop novel medicines using Santaris Pharma's proprietary Locked Nucleic Acid (LNA) Drug Platform. (Logo: http://photos.prnewswire.com/prnh/20100111/SPLOGO) Under the terms of the...

2013-04-15 08:28:43

QUÉBEC CITY, April 15, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") announced today that David A. Dodd has been appointed President and Chief Executive Officer of the Company, succeeding Juergen Engel, PhD.  Mr. Dodd has also been appointed director on the Company's Board of Directors. Aeterna Zentaris Inc. is an oncology and endocrinology drug development company currently investigating treatments for various unmet...

2013-04-12 08:25:04

QINGDAO, China and ROCKVILLE, Md., April 12, 2013 /PRNewswire/ -- Synutra International, Inc. (NASDAQ: SYUT), ("Synutra" or the "Company"), which owns subsidiaries in China that produce, market and sell nutritional products for infants, children and adults, announced that it has received the required approvals from China's National Development and Reform Commission (NDRC) and its Ministry of Commerce (MC) for the construction of a new drying facility in Carhaix, France. As originally...

2013-04-08 00:20:36

IGDRASOL will present updates on its proprietary late clinical stage NBN-Pac formulations, including Cynviloq(TM), a paclitaxel nanoparticle, and the recently acquired IG-004, a vitamin E-based paclitaxel emulsion. Highlights of the findings include the studies and comparison of pharmacokinetic and pharmacodynamic properties as well as drug release characteristics to Abraxane®, an albumin-based paclitaxel nanoparticle (nab-paclitaxel). SAN DIEGO and FOUNTAIN VALLEY, Calif., April...